文献速递血脂与心血管预防心律失常瓣膜病与结构性心脏病

面向心血管全谱系的药物与器械个体化抗血栓管理

Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.
PubMed 文献 · Eur Heart J · 2022-01-01

本文综述了心血管系统不同部位血栓形成与栓塞的机制及抗血栓策略。静脉血栓、房颤、心梗、瓣膜病及动脉粥样硬化等场景下,抗凝药与器械选择需依据血栓部位、患者特征及出血风险个体化。维生素K拮抗剂用于机械瓣,新型口服抗凝药为多数其他心血管情况首选,高出血风险者可选卵圆孔未闭或左心耳封堵器,抗血小板药用于冠心病、卒中及外周动脉疾病二级预防。

要点

  • 机械瓣患者优选维生素K拮抗剂,多数其他心血管情况首选新型口服抗凝药。
  • 高出血风险者可选卵圆孔未闭封堵器或左心耳封堵器替代抗凝。
  • 冠心病、卒中及外周动脉疾病二级预防优选阿司匹林和/或P2Y12拮抗剂。

核心结论

  • 推荐根据血栓形成与栓塞部位及患者特征,差异化、个体化使用抗凝药、血小板抑制剂和器械。

研究设计与样本

  • 综述,检索范围未在原文中报告。

主要发现

  • 静脉系统血栓可导致静脉血栓形成、肺栓塞及通过卵圆孔未闭引起外周栓塞包括缺血性卒中。
  • 左心房及心耳血栓见于房颤,心室血栓见于梗死。
  • 血栓可形成于原生或人工主动脉瓣、主动脉(尤其溃疡、夹层和腹主动脉瘤处)及脑和外周动脉。
  • 血栓性闭塞可发生于供应心、脑、肾和四肢等生命器官的动脉。

关键数值与推荐

  • 机械瓣患者优选维生素K拮抗剂。
  • 多数其他心血管情况首选新型口服抗凝药,尤其静脉血栓栓塞和房颤。
  • 高出血风险患者优选卵圆孔未闭封堵器或左心耳封堵器等器械。
  • 冠心病、卒中及外周动脉疾病二级预防优选阿司匹林和/或P2Y12拮抗剂,可单用或联用。

临床怎么用

  • 临床决策需综合血栓部位、栓塞风险、患者特征及出血风险选择抗凝药、抗血小板药或器械。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravascular thrombus formation and embolization are among the most frequent events leading to a number of cardiovascular conditions with high morbidity and mortality. The underlying causes are stasis of the circulating blood, genetic and acquired coagulation disorders, and reduced antithrombotic or prothrombotic properties of the vascular wall (Virchow's triad). In the venous system, intravascular thrombi can cause venous thrombosis and pulmonary and even peripheral embolism including ischaemic stroke [through a patent foramen ovale (PFO)]. Thrombi in the left atrium and its appendage or ventricle form in the context of atrial fibrillation and infarction, respectively. Furthermore, thrombi can form on native or prosthetic aortic valves, within the aorta (in particular at sites of ulcers, aortic dissection, and abdominal aneurysms), and in cerebral and peripheral arteries causing stroke and critical limb ischaemia, respectively. Finally, thrombotic occlusion may occur in arteries supplying vital organs such the heart, brain, kidney, and extremities. Thrombus formation and embolization can be managed with anticoagulants and devices depending on where they form and embolize and on patient characteristics. Vitamin K antagonists are preferred in patients with mechanical valves, while novel oral anticoagulants are first choice in most other cardiovascular conditions, in particular venous thromboembolism and atrial fibrillation. As anticoagulants are associated with a risk of bleeding, devices such as occluders of a PFO or the left atrial appendage are preferred in patients with an increased bleeding risk. Platelet inhibitors such as aspirin and/or P2Y12 antagonists are preferred in the secondary prevention of coronary artery disease, stroke, and peripheral artery disease either alone or in combination depending on the clinical condition. A differential and personalized use of anticoagulants, platelet inhibitors, and devices is recommended and reviewed in this article.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lüscher TF, Davies A, Beer JH, et al. Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. Eur Heart J. 2022. PMID: 34624084. doi:10.1093/eurheartj/ehab642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。